Company intelligence / Profile preview
Chumakov Federal Scientific Center
- Ownership
- Private
- Development stage
- Other
Overview
Chumakov Federal Scientific Center is a leading Russian institution specializing in medical virology with a long history dating back to its founding by Dr. Mikhail Chumakov. It has developed several globally significant vaccines—including oral polio vaccine—and continues to supply up to ~70% of Russia’s demand for polio-, rabies-, tick-borne encephalitis-, yellow fever-vaccines. The center developed CoviVac—an inactivated whole-virus COVID‑19 vaccine—which was registered by the Russian Ministry of Health in February 2021 and produced at scale through partnerships like Nanolek.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineRecombinant proteinMonoclonal antibody
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Chumakov Federal Scientific Center.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chumakov Federal Scientific Center.